SI-BONE, Inc.
About SI-BONE, Inc.
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $200.9M
- Net income
- -$18.9M
- Total assets
- $238.6M
- Market cap
- $670.6M
- Gross margin
- 79.0%
- Operating margin
- -21.1%
- Net margin
- -18.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $167.2M
- Cost of revenue
- $35.1M
- Gross profit
- $132.1M
- Operating expenses
- $167.4M
- Operating income
- -$35.2M
- Income tax
- $6.0M
- Net income
- -$30.9M
- EPS (basic)
- $-0.75
- EPS (diluted)
- $-0.75
Balance sheet
- Total assets
- $230.4M
- Current assets
- $207.8M
- Total liabilities
- $63.5M
- Current liabilities
- $27.1M
- Shareholders’ equity
- $167.0M
Cash flow
- Operating cash flow
- -$12.4M
- Investing cash flow
- $12.6M
- Financing cash flow
- $2.0M
- Net cash flow
- $1.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $670.6M
- EPS (diluted)
- $-0.75
- Shares outstanding
- 44.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 17, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $18.9M in FY2025.
- Revenue grew 128% from FY2020 to FY2024.
- Gross margin of 79.0%, net margin -18.5%.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SI-BONE, Inc..
Write a review
News about SI-BONE, Inc.
News & sentiment via Polygon.io
